Sulforaphane, a natural compound first isolated from a precursor in Brassica plants, has shown therapeutic potential, but has also proven too unstable to be manufactured as a drug on commercial scale. Evgen Pharma (LON:EVG) has developed a proprietary technology - Sulforadex® - that allows the synthesis of sulforaphane in the form of a stable, solid powder that can be easily manufactured as an oral drug. The Company has then developed several analogues with slightly different biophysical
21 Feb 2018
Evgen Pharma PLC - Harnessing Sulforaphane's Therapeutic Properties
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Evgen Pharma PLC - Harnessing Sulforaphane's Therapeutic Properties
Evgen Pharma Plc (EVG:LON) | 0.8 0 0.0% | Mkt Cap: 3.42m
- Published:
21 Feb 2018 -
Author:
Dr. Riccardo Lowi -
Pages:
4
Sulforaphane, a natural compound first isolated from a precursor in Brassica plants, has shown therapeutic potential, but has also proven too unstable to be manufactured as a drug on commercial scale. Evgen Pharma (LON:EVG) has developed a proprietary technology - Sulforadex® - that allows the synthesis of sulforaphane in the form of a stable, solid powder that can be easily manufactured as an oral drug. The Company has then developed several analogues with slightly different biophysical